Ituxredi

Rituximab, the active ingredient in Ituxredi, is a monoclonal antibody presented as an intravenous solution for intravenous use. It targets CD20‑positive B‑lymphocytes and is employed in the treatment of certain cancers and autoimmune disorders in adult patients.

GNH USA supplies Ituxredi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide.

Ituxredi (rituximab) is indicated for diseases driven by CD20‑positive B‑cell activity. - Non‑Hodgkin lymphoma: induces remission by depleting malignant B‑cells. - Chronic lymphocytic leukemia: improves survival through B‑cell depletion. - Rheumatoid arthritis: reduces joint inflammation by targeting pathogenic B‑cells. - Granulomatosis with polyangiitis: controls vasculitis by eliminating autoreactive B‑cells. - Microscopic polyangiitis: achieves disease control through B‑cell suppression.

Adverse reactions may occur with rituximab therapy and are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions: fever, chills, rigors, or hypotension during administration. - Infections: upper respiratory or urinary tract infections. - Cytopenias: transient neutropenia or thrombocytopenia. - Gastrointestinal upset: nausea, vomiting, or diarrhea.

Serious or Rare Side Effects: - Severe infusion reactions: bronchospasm, angioedema, or anaphylaxis. - Hepatitis B reactivation in carriers. - Progressive multifocal leukoencephalopathy (PML). - Cardiac arrhythmias or myocardial infarction. - Severe infections such as sepsis.

Prior to initiating rituximab therapy, clinicians should assess patient history and monitor for potential complications. - Screen for hepatitis B: test for HBsAg and anti‑HBc before treatment. - Evaluate infection risk: treat active infections before infusion. - Monitor blood counts: perform baseline and periodic CBC. - Assess cardiac status: caution in patients with recent myocardial infarction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Rituximab may interact with other agents that affect immune function or increase infection risk.

Major Interactions (Avoid): - Live vaccines: contraindicated during and for several months after therapy. - Concurrent chemotherapy agents that cause profound immunosuppression.

Moderate Interactions (Monitor Closely): - Antiviral prophylaxis (e.g., acyclovir) when hepatitis B risk is present. - Immunoglobulin replacement therapy: may reduce rituximab efficacy. - Corticosteroids: may augment immunosuppression, requiring infection surveillance.